Skip to main content

Table 3 Analysis of lipid and glycemic parameters

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

 

n

Baseline mean ± SD

After administration mean ± SD

Difference

Percentage

TC (mmol/L)

3316

5.76 ± 1,03

5.45 ± 0.94

-0.31 ± 1.00 §

-5.4%

LDL-C (mmol/L)

2226

3.19 ± 0.95

3.25 ± 0.81

0.05 ± 0.90 ‡

1.6%

TG (mmol/L)

3316

3.72 ± 2.45

2.03 ± 1.50

-1.69 ± 2.08 §

-45.4%

HDL-C (mmol/L)

2818

1.18 ± 0.32

1.34 ± 0.35

0.17 ± 0.25 §

14.0%

non-HDL-C (mmol/L)

2818

4.57 ± 0.99

4.11 ± 0.96

-0.46 ± 0.09 §

-10.1%

TG/HDL

1818

3.49 ± 2.75

1.70 ± 1.59

-1.79 ± 2.31 §

-51.3%

HbA1c (%)

3316

7.69 ± 1.52

7.22 ± 1.28

-0.47 ± 1.21 §

-6.2%

FBG (mmol/L)

2387

9.00 ± 3.46

7.81 ± 2.89

-1.19 ± 3.33 §

-13.2%

HOMA-R

102

4.46 ± 4.91

3.38 ± 3.83

-1.08 ± 4.78 †

-24.3%

  1. "Difference" indicates the value for the change from baseline. "Percentage" indicates rate of change from baseline. A paired t-test was used to assess statistically significant differences from baseline for each group. Symbols for p values in this and the tables that follow: †: p < 0.05, ‡: p < 0.01, §: p < 0.001